ICG and SLN Mapping

NCT05859971 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: SLN mapping using technetium-99m +/- isosulfan blue dye
DEVICE: SLN mapping with ICG fluorescence using the Asimov Platform

Sponsor

University of Wisconsin, Madison

Collaborators

[object Object]
[object Object]